**Specifications table**TableSubject areaBiologyMore specific subject areaDyslipidemia and cardiovascular riskType of dataTables and FiguresHow data was acquiredWorldwide surveyData formatAnalyzedExperimental factorsObservational, longitudinal registryExperimental featuresComparison of lipid lowering therapies administered in patients with coronary heart disease, as well as LDL-C target achievement.Data source locationInstitut für Herzinfarktforschung, Ludwigshafen, GermanyData accessibilityData are included in this article

**Value of the data**•These data have been collected under real life conditions across the world.•Stratification per country can help to facilitate a scientific dialogue for the benefit of coronary patients in these countries, but also help to compare treatment standards between geographies of the world.•The data presented can help to guide treatment decisions for novel lipid lowering agents.

1. Data {#s0005}
=======

See [Fig. 1](#f0005){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.Fig. 1LDL-C target attainment for LLT-treated patients by region Legend: \**p*\<0.05 for overall comparison.Fig. 1Table 1Predictors of LDL-C target value attainment among treated CHD patients.Table 1Full modelStepwise modelOR95% CI*P* valueOR95% CI*P* valueAge \>70 years1.090.97--1.230.166------Female0.720.62--0.83\<0.0010.720.63--0.84\<0.001BMI \>30 kg/m^2^0.830.72--0.950.0070.820.71--0.940.004Current smoking0.820.69--0.990.0350.810.68--0.970.022Sedentary lifestyle0.860.76--0.970.0110.860.76--0.970.012Stable angina0.880.77--0.990.0410.880.77--0.990.040Chronic kidney disease1.200.98--1.460.076------Type 2 diabetes mellitus1.701.51--1.92\<0.0011.721.53--1.93\<0.001History of chronic heart failure0.870.73--1.040.133------Hypertension0.810.71--0.920.0010.820.72--0.930.002Statin dose (\>20 mg/day atorvastatin dose equivalent)1.0101.007--1.013\<0.0011.0101.007--1.013\<0.001[^1]Table 2Regional differences in lipid-lowering therapy.Table 2Asia (*N*=2562)Europe (*N*=2777)Middle East (*N*=1031)*P* valueStatin monotherapy86.2%79.8%79.6%\<0.001Statin+ezetimibe7.7%11.6%14.6%\<0.001Statin+other non-statin5.3%6.7%5.0%0.047Non-statin monotherapy0.8%2.0%0.7%\<0.001Atorvastatin dose equivalent (mean±SD mg/day)[a](#tbl2fna){ref-type="table-fn"}20±1527±2030±18\<0.0001Atorvastatin dose equivalent (median \[IQR\] mg/day)[a](#tbl2fna){ref-type="table-fn"}20 (10, 20)20 (10, 40)20 (20, 40)[^2][^3]

2. Experimental design, materials and methods {#s0010}
=============================================

DYSIS II CHD was a multicenter, longitudinal, observational study that included 6794 patients from 18 countries in Europe, the Middle East, South-, Southeast- and East-Asia [@bib1].

The study was approved by the relevant ethics committees and carried out in agreement with local laws.

Inclusion criteria were as follows: 1) provision of written informed consent, 2) aged ≥18, 3) attending an outpatient appointment for stable CHD 2012--2014, 4) availability of a full fasting or non fasting lipid profile from within the previous 12 months, and 5) not participating in a clinical trial.

The ESC/EAS dyslipidemia guidelines (2011) were used as a reference in order to determine target value attainment [@bib2]. Low density lipoprotein (LDL-C) treatment target thus was \<70 mg/dl. Use of LLT was documented, including use of statin and combination therapy. We also determined the statin dose administered, calculated as atorvastatin equivalent doses [@bib3].

Data were collected in an electronic case report form and processed in a central web-based database at the Institut für Herzinfarktforschung, Ludwigshafen, Germany. It was used for both collection and storage of the data.

SAS version 9.3 (Cary, NC, USA) was used for performing the calculations. Data are presented as absolute numbers and percentages (*n*/*N*). Between-group differences were evaluated using a chi squared test. Multivariable logistic regression was used to calculate odds ratios for factors predictive of LDL-C target attainment. Both the results of the full model and a stepwise forward selection model are given.
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=============================================

Supplementary material.

The work was funded by *Merck & Co., Inc.,* *Kenilworth, NJ, USA*. The authors of the present study would like to thank all DYSIS II CHD investigators for their contribution to the successful completion of this study.

Supplementary data associated with this article can be found in the online version at [10.1016/j.dib.2018.04.092](https://doi.org/10.1016/j.dib.2018.04.092){#ir0005}.

[^1]: Legend: BMI, body mass index; CI, confidence interval; OR, odds ratio.

[^2]: SD, standard deviation; IQR, interquartile range.

[^3]: In statin treated patients.
